HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association of metreleptin treatment and dietary intervention with neurological outcomes in Celia's encephalopathy.

Abstract
Celia's encephalopathy (progressive encephalopathy with/without lipodystrophy, PELD) is a recessive neurodegenerative disease that is fatal in childhood. It is caused by a c.985C>T variant in the BSCL2/seipin gene that results in an aberrant seipin protein. We evaluated neurological development before and during treatment with human recombinant leptin (metreleptin) plus a dietary intervention rich in polyunsaturated fatty acids (PUFA) in the only living patient. A 7 years and 10 months old girl affected by PELD was treated at age 3 years with metreleptin, adding at age 6 omega-3 fatty acid supplementation. Her mental age was evaluated using the Battelle Developmental Inventory Screening Test (BDI), and brain PET/MRI was performed before treatment and at age 5, 6.5, and 7.5 years. At age 7.5 years, the girl remains alive and leads a normal life for her mental age of 30 months, which increased by 4 months over the last 18 months according to BDI. PET images showed improved glucose uptake in the thalami, cerebellum, and brainstem. This patient showed a clear slowdown in neurological regression during leptin replacement plus a high PUFA diet. The aberrant BSCL2 transcript was overexpressed in SH-SY5Y cells and was treated with docosahexaenoic acid (200 µM) plus leptin (0.001 mg/ml) for 24 h. The relative expression of aberrant BSCL2 transcript was measured by qPCR. In vitro studies showed significant reduction (32%) in aberrant transcript expression. This therapeutic approach should be further studied in this devastating disease.
AuthorsDavid Araújo-Vilar, Rosario Domingo-Jiménez, Álvaro Ruibal, Pablo Aguiar, Salvador Ibáñez-Micó, Miguel Garrido-Pumar, Miguel Ángel Martínez-Olmos, Concepción López-Soler, Cristina Guillín-Amarelle, María González-Rodríguez, Antonio Rodríguez-Núñez, Julián Álvarez-Escudero, Mercedes Liñares-Paz, Blanca González-Méndez, Silvia Rodríguez-García, Sofía Sánchez-Iglesias
JournalEuropean journal of human genetics : EJHG (Eur J Hum Genet) Vol. 26 Issue 3 Pg. 396-406 (03 2018) ISSN: 1476-5438 [Electronic] England
PMID29367704 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BSCL2 protein, human
  • Fatty Acids, Unsaturated
  • GTP-Binding Protein gamma Subunits
  • Leptin
  • metreleptin
Topics
  • Brain Diseases (diet therapy, drug therapy, genetics)
  • Cell Line, Tumor
  • Child
  • Diet
  • Fatty Acids, Unsaturated (administration & dosage, therapeutic use)
  • Female
  • GTP-Binding Protein gamma Subunits (genetics, metabolism)
  • Humans
  • Leptin (administration & dosage, analogs & derivatives, therapeutic use)
  • Lipodystrophy (diet therapy, drug therapy, genetics)
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: